直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • News
  • Finnegan Facts
  • History
    • Finnegan VISION
    • Finnegan FORWARD
  • Pro Bono
  • Management
    • Pricing & Alternative Fee Arrangements
    • AFA Models We Offer
    • Contingency Fees
    • AI + KM

Media Mention

Trust Can't Boot Abbott's Humira® Patent Challenge

October 14, 2011

Law360

On October 14, 2011, District Court Judge Paul A. Crotty denied The Mathilda and Terence Kennedy Institute of Rheumatology Trust’s motion to dismiss a suit brought by Abbott Laboratories seeking to invalidate a patent allegedly covering Abbott’s blockbuster arthritis drug Humira®.  Abbott Laboratories is represented by Finnegan in this matter.

Related Practices

Global IP Enforcement, Litigation, and Trials

Related Industries

Life Sciences

Pharmaceutical

Related News

Commentary

New Appellate Opinion in Amazon Biometric Data Case May Signal ‘Narrowing’ Scope of BIPA Litigation, Experts Say

May 20, 2026

Award/Ranking

Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award

May 13, 2026

Press Release

Finnegan Secures Decisive ITC Victory for Innoscience in Final Determination

May 11, 2026

Award/Ranking

Associates Rank Finnegan “Best of the Best” in BTI Associate Satisfaction Survey

May 7, 2026

Award/Ranking

61 Finnegan Attorneys Recognized on the 2025 Capital Pro Bono Honor Roll

May 7, 2026

Commentary

Justices to Side with Generic Drugmakers in Patent Spat, Attorneys Predict

May 5, 2026

Announcement

Finnegan Partner Ningling Wang Becomes President of Licensing Executives Society International

May 4, 2026

Award/Ranking

Finnegan Wins IP Firm of the Year at the 2026 LSPN Awards

May 1, 2026

Press Release

Finnegan Enhances Its German and European IP Practice with Björn Kalbfus

April 30, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP